Table of Content

1. Introduction to Oncolytic Virus
1.1 Outline of Oncolytic Virotherapy
1.2 Trail from Genesis to Biogenetics


2. Primer of Virotherapy in Malignancies
2.1 Oncolytic Viruses towards Cancer
2.2 Approaches for Targeting Tumor Cells
2.2.1 Pro Apoptotic Targeting
2.2.2 Translational Targeting
2.2.3 Transcriptional Targeting
2.2.4 Transductional Targeting


3. Viral Oncolysis Mechanism of Action
3.1 Viral Entry into Cancerous Cells
3.2 Efficacy Routes Followed by Oncogenic Viruses
3.3 Mechanism of Tumor Specificity
3.3.1 Defective Anti-Viral Responses
3.3.2 Receptor Targeting for Tumor Selective Intake
3.3.3 Targeting to Tumor Specific Promoters
3.3.4 Viral Gene Deletions
3.3.5 Proteolytic Processing of Virus Particles in Tumor Microenvironment


4. Oncolytic Viruses Immunotherapy Overview
4.1 Stimulation of Antitumor Immune Responses
4.2 Oncolytic Viruses as Cancer Vaccines


5. Varieties of Viruses Casted as Oncolytic Viruses
5.1 Oncolytic Wild Type Viruses
5.1.1 Reovirus (Respiratory Enteric Orphan Virus)
5.1.2 Vesicular Stomatitis Virus (VSV)
5.1.3 Newcastle Disease Virus (NDV)
5.1.4 Myxoma

5.2 Genetically Engineered Oncolytic Viruses
5.2.1 Adenoviruses
5.2.2 Herpes Simplex Virus
5.2.3 Vaccinia Virus


6. Potential Oncolytic Virus Immunotherapy for Cancers
6.1 Breast Cancer
6.2 Lung Cancer
6.3 Prostate Cancer
6.4 Melanoma
6.5 Brain Tumor
6.6 Blood Cancer


7. Global Oncolytic Virus Immunotherapy Therapy Market Overview
7.1 Preface towards Oncolytic Virus Arcade
7.2 Market Aspects of Approved Oncolytic Viruses


8. Oncolytic Virus Immunotherapy Clinical Pipeline Overview
8.1 By Phase
8.2 By Company
8.3 By Country
8.4 By Indication
8.5 By Patient Segment


9. Global Oncolytic Virus Immunotherapy – Availability, Dosage & Price Analysis
9.1 Imlygic (Talimogene laherparepvec)
9.2 Oncorine (H101)


10. Research Progress & Medical Advancement in Oncolytic Virus Therapy Market
10.1 Oncolytic Virus Therapy Development as a Cancer Vaccine
10.2 Oncolytic Virus Therapy Collaboration with T-Cell Therapy for Advanced Results
10.3 Preliminary Effectiveness of Oncolytic Virus Therapy in Killing Malignant Tumor
Cells in Children
10.4 Combined Study of Oncolytic Virus Therapy and CAR-T Cell Therapy by City of
Hope Researchers
10.5 TG4001 & TG6002 Positive Clinical Results against HPV-Induced Cancers
10.6 Pelareorep-Anti-PD-1 Combination for the Treatment of Locally Advanced or
Metastatic Triple-Negative Breast Cancer
10.7 Adenovirus E3 Region to Substantially Improve Oncolytic Efficacy & Potency
10.8 University of Helsinki Novel Solution for Advancing Oncolytic Virus Therapy
10.9 Valo Therapeutics Technology Acquisition for Advancing Oncolytic Therapy
10.10 Mayo Clinic to Expand Oncolytic Virus Therapy against Multiple Myeloma


11. Strategic Partnership & Collaborations to Advance the Oncolytic Virus Therapy Market
11.1 Mustang Bio & Nationwide Children’s Hospital to Undergo Collaboration for
Oncolytic Virus Therapy for Glioblastoma
11.2 Pfizer & Western Oncolytics Collaboration Announcement for Novel Oncolytic
Treatment
11.3 Tessa Therapeutics & Vyriad to Synergistically Boost the Novel Oncolytic
Treatment
11.4 Boehringer Ingelheim & Vira Therapeutics to Develop Next Generation Oncolytic
Virus Therapy for the Cancer Patients
11.5 Regeneron & Vyriad Therapeutics Collaboration for Unravelling Oncoytic Virus
Therapy for Cancer Treatment
11.6 DNAtrix & Valo Therapeutics Collaboration for Evaluating Peptide Based
Oncolytic Therapy for the Cancer Patients
11.7 Pfizer & Ignite Immunotherapy to Collaboration for Developing Next-Generation
Oncolytic Virus Therapy
11.8 AbbVie & Turnstone Biologics to Collaborate for Next-Generation Oncolytic Viral
Immunotherapies
11.9 ABL Europe & SillaJen to Expand Oncolytic Virus Therapy Market
11.10 PsiOxus & BMS Ink Collaboration for the Development of Transgenic Oncolytic
Therapy


12. Global Oncolytic Virus Immunotherapy Clinical Trials By Company, Indication & Phase
12.1 Research
12.2 Preclinical
12.3 Clinical
12.4 Phase-I
12.5 Phase-I/II
12.6 Phase-II
12.7 Phase-II/III
12.8 Phase-III


13. Marketed Oncolytic Virus Immunotherapy Clinical Insight
13.1 IMLYGIC
13.2 Oncorine


14. Global Oncolytic Virus Immunotherapy Market Dynamics
14.1 Market Drivers
14.2 Growth Inhibitors


15. Global Oncolytic Virus Immunotherapy Market Future Outlook


16. Competitive Landscape
16.1 BioVex Inc.
16.2 Cell Genesys
16.3 Crusade Laboratories
16.4 Genelux Corporation
16.5 Jennerex Biotherapeutics
16.6 Lokon Pharma
16.7 Merck
16.8 MultiVir
16.9 Oncolys BioPharma
16.10 Oncolytics Biotech
16.11 Oncos Therapeutics (Targovax)
16.12 PsiOxus Therapeutics
16.13 Shanghai Sunway Biotech
16.14 Takara Bio
16.15 VCN Biosciences
16.16 ViroTarg
16.17 Vyriad



List of Figures


Figure 1-1: Demonstration of Categorization of Oncolytic Viruses
Figure 1-2: Illustration of Major Events in Clinical Virotherapy

Figure 2-1: Potential Advantages of Oncolytic Viruses over Conventional Therapies

Figure 3-1: The Diagrammatic Representation of Entry of Virions into Cancerous cells
Figure 3-2: Route of Anti-tumoral Efficacy of Oncolytic Viruses
Figure 3-3: Mechanism of Tumor Destruction by Oncolytic Viruses
Figure 3-4: Categorization Followed by Oncolytic Viruses for Tumor Selectivity

Figure 4-1: Demonstration of Phases of Immune Responses Elicited by the Oncolytic Viruses

Figure 5-1: Categorization of Oncolytic Viruses over the Basis of their Behavior
Figure 5-2: Diagrammatic Representation of Oncolysis Shown by Reovirus
Figure 5-3: Mechanism of Oncolytic Behavior of Adenoviruses

Figure 6-1: Selectively Killing of Prostate Cancer Cells by Oncolytic M-Protein Strains of VSV
Figure 6-2: Proposed Treatment of Oncolytic Viruses for Hematological Malignancies

Figure 7-1: Global - Oncolytic Virus Immunotherapy Market Opportunity (US$ Million), 2020 -2026

Figure 8-1: Global Oncolytic Virus Pipeline by Phase (%), 2020 till 2026
Figure 8-2: Oncolytic Virus Pipeline by Phase (Numbers), 2020 till 2026
Figure 8-3: Global - Oncolytic Virus Immunotherapy Clinical Trials by Company (Numbers), 2020 till 2026
Figure 8-4: Global - Oncolytic Virus Immunotherapy Clinical Trials by Country (Numbers), 2020 till 2026
Figure 8-5: Global - Oncolytic Virus Immunotherapy Clinical Trials by Indication (Numbers), 2020 till 2026
Figure 8-6: Global - Oncolytic Virus Immunotherapy Clinical Trials by Patient Segment (Numbers), 2020 till 2026

Figure 9-1: Imlygic – US & European Patent Expiration Year
Figure 9-2: Imlygic – Price of 1 Million PUF/ml & 100 Million PUF/ml Injectable Suspension (US$), September’2020
Figure 9-3: Imlygic – Dose for Initial Treatment Cycle & Subsequent Treatment Cycle (Million PUF/ml), September’2020
Figure 9-4: Imlygic – Duration of Initial & Subsequent Treatment Cycle (weeks), September’2020
Figure 9-5: Imlygic – Average Price of Initial Treatment Cycle & Each Subsequent Treatment Cycle (US$), September’2020
Figure 9-6: Imlygic – Volume Administered by Size of Lesion (ml), September’2020
Figure 9-7: Oncorine: Cost of Single Dose & Single Treatment Course (US$), September’2020
Figure 9-8: Oncorine – Duration of Treatment Cycle by Type of Cancer (Days), September’2020

Figure 14-1: Major Drivers for the Oncolytic Virus Therapies
Figure 14-2: Major Challenges Faced by Oncolytic Viral Therapies

Figure 16-1: Lokon Pharma - Clinical Pipeline
Figure 16-2: MultiVir –Clinical Pipeline
Figure 16-3: Oncolys BipoPharma- Clinical Pipeline
Figure 16-4: Oncos Therapeutics- Clinical Pipeline
Figure 16-5: Vyriad- Clinical Pipeline